Twist Bioscience (NASDAQ:TWST) Reaches New 1-Year High – Here’s Why

Twist Bioscience Corporation (NASDAQ:TWST)’s share price reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $140.95 and last traded at $135.2480, with a volume of 613748 shares changing hands. The stock had previously closed at $116.10.

Analyst Ratings Changes

TWST has been the topic of several recent research reports. UBS Group set a $89.00 target price on shares of Twist Bioscience in a research report on Monday, June 15th. Barclays increased their price target on Twist Bioscience from $65.00 to $95.00 and gave the company an “overweight” rating in a research note on Wednesday, June 24th. Guggenheim lifted their price objective on Twist Bioscience from $60.00 to $107.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a research report on Wednesday, June 24th. Finally, Evercore lowered shares of Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 price target for the company. in a report on Monday, July 6th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Twist Bioscience has a consensus rating of “Moderate Buy” and an average price target of $98.30.

Twist Bioscience Stock Performance

The firm has a market capitalization of $8.74 billion, a P/E ratio of -62.61 and a beta of 2.14. The company’s 50 day moving average is $96.57 and its 200-day moving average is $68.42. The company has a quick ratio of 2.38, a current ratio of 2.67 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last issued its earnings results on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The firm had revenue of $118.38 million during the quarter, compared to the consensus estimate of $114.55 million. During the same period in the previous year, the firm earned $0.33 earnings per share. The business’s quarterly revenue was up 23.2% on a year-over-year basis. As a group, equities analysts anticipate that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, SVP Paula Green sold 291 shares of Twist Bioscience stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $87.32, for a total transaction of $25,410.12. Following the completion of the transaction, the senior vice president owned 120,414 shares in the company, valued at approximately $10,514,550.48. The trade was a 0.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Adam Laponis sold 2,399 shares of the business’s stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $94.33, for a total value of $226,297.67. Following the sale, the chief financial officer directly owned 110,276 shares of the company’s stock, valued at $10,402,335.08. This represents a 2.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 151,529 shares of company stock valued at $17,708,772 over the last three months. Corporate insiders own 3.08% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Quarry LP purchased a new stake in Twist Bioscience in the 3rd quarter valued at $28,000. Western Wealth Management LLC purchased a new position in Twist Bioscience during the 1st quarter worth $31,000. Strs Ohio bought a new stake in shares of Twist Bioscience in the 1st quarter worth $33,000. Strategic Advocates LLC grew its position in Twist Bioscience by 562.7% in the 4th quarter. Strategic Advocates LLC now owns 1,067 shares of the company’s stock worth $34,000 after purchasing an additional 906 shares in the last quarter. Finally, SBI Securities Co. Ltd. increased its position in shares of Twist Bioscience by 68.9% during the fourth quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company’s stock valued at $44,000 after acquiring an additional 571 shares during the last quarter.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.